Clinical Trial: NCT04905316
A Study of Canakinumab With Chemotherapy, Radiation Therapy, and Durvalumab in People With Lung Cancer
Status:
COMPLETEDPhase:
Phase 2| Lead Sponsor: | Memorial Sloan Kettering Cancer Center |
| Information Provided By: | Memorial Sloan Kettering Cancer Center |
| Last Update Posted: | 2026-07-08 |
Study Overview
Brief Summary
The researchers are doing this study to find out whether canakinumab in combination with chemoradiation and durvalumab is an effective and safe treatment for people with locally advanced non-small cell lung cancer (NSCLC).
Official Title
Phase I/II Study of Canakinumab With Chemoradiation and Durvalumab for Unresected Locally-Advanced Non-Small Cell Lung Cancer (CHORUS)
Conditions
Non-small Cell Lung Cancer
Intervention / Treatment
- Drug: Canakinumab
- Drug: Durvalumab
- Radiation: Radiation therapy
- Drug: Chemotherapy
Other Study ID Numbers
- 21-004
Start Date (Actual)
2021-05-21
Primary Completion Date (Actual)
2026-07-06
Study Completion Date (Actual)
2026-07-06
Enrollment (Actual)
41
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | Memorial Sloan Kettering Cancer Center |
| Information Provided By: | Memorial Sloan Kettering Cancer Center |
| Last Update Posted: | 2026-07-08 |
Study Overview
Brief Summary
The researchers are doing this study to find out whether canakinumab in combination with chemoradiation and durvalumab is an effective and safe treatment for people with locally advanced non-small cell lung cancer (NSCLC).
Official Title
Phase I/II Study of Canakinumab With Chemoradiation and Durvalumab for Unresected Locally-Advanced Non-Small Cell Lung Cancer (CHORUS)
Conditions
Non-small Cell Lung Cancer
Intervention / Treatment
- Drug: Canakinumab
- Drug: Durvalumab
- Radiation: Radiation therapy
- Drug: Chemotherapy
Other Study ID Numbers
- 21-004
Start Date (Actual)
2021-05-21
Primary Completion Date (Actual)
2026-07-06
Study Completion Date (Actual)
2026-07-06
Enrollment (Actual)
41
Study Type
Interventional
Phase
Phase 2